Provectus Pharmaceuticals, Inc. (PVCT.OB) Moving Forward with Licensure of PV-10 for Metastatic Melanoma, Successfully Concludes End-of-Phase 2 FDA Meeting
Provectus Pharmaceuticals, Inc., a development-stage biopharma specialist creating innovative new therapies for the oncology (focused on melanoma) and dermatology markets,…